Obviously, with the FDA's issues with recruitment and retention, committing to adding even more people is a significant thing, right?

Oh, yeah.

That's a constant feature of the PDUFA negotiations, cycle in and cycle out, right? and takes on a real urgency now as they try to restaff following the various personnel moves at the beginning of the second Trump administration.

So it's interesting that they're not getting a blank check from industry as much as industry has been supportive of the efforts to ensure continuity and experience and strength at the FDA.

They're not just going to get all the money.

They want immediately to do whatever they want in terms of hiring.

They have to show that they are hiring in order to get some of these fees.

First of all, Matt, I wanted to ask you, you know, which naming convention do you prefer for the meetings? Do you like 306090 or ABC better?

Obviously, with the FDA's issues with recruitment and retention, committing to adding even more people is a significant thing, right?

Oh, yeah.

That's a constant feature of the PDUFA negotiations, cycle in and cycle out, right? and takes on a real urgency now as they try to restaff following the various personnel moves at the beginning of the second Trump administration.

So it's interesting that they're not getting a blank check from industry as much as industry has been supportive of the efforts to ensure continuity and experience and strength at the FDA.

They're not just going to get all the money.

They want immediately to do whatever they want in terms of hiring.

They have to show that they are hiring in order to get some of these fees.

First of all, Matt, I wanted to ask you, you know, which naming convention do you prefer for the meetings? Do you like 306090 or ABC better?